



## PRESS RELEASE

### **PROTEOME SCIENCES PRESENTING ON BLOOD BIOMARKERS AND TAU TARGETED THERAPIES AT GLOBAL ALZHEIMER'S DISEASE CONFERENCE, AD/PD 2015.**

**Cobham, UK, March 18<sup>th</sup> 2015:** Proteome Sciences plc, a global leader in proteomics, is pleased to announce that it will present four posters at the 12<sup>th</sup> International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders which opens today in Nice, France. The posters highlight recent developments in Proteome Sciences' proprietary biomarker discovery technologies for enhanced biomarker discovery, mapping of cell signaling pathways and targeted mass spectrometry methods for a blood biomarker of Alzheimer's disease.

**Poster #063 (Thursday March 19<sup>th</sup>) – Application of a global (phospho)proteomic workflow to analyse fresh-frozen brain tissue in transgenic models of neurodegeneration**

Application of SysQuant<sup>®</sup> to map cell signaling and regulatory pathway changes in response to kinase inhibitor treatment.

**Poster #178 (Friday March 20<sup>th</sup>) – Glycosylation of human plasma clusterin provides novel biomarkers of Alzheimer's disease**

Demonstration of a targeted method for measurement of clusterin isoforms that predict Alzheimer's disease severity/progression

**Poster #295 (Friday March 20<sup>th</sup>) – Casein kinase 1 inhibitors beneficially modulate tau phosphorylation and cell signaling pathways in a transgenic model of human tauopathy**

Multiple pathway changes occurring in a phospho-tau dose-dependent manner in human Alzheimer's disease are reversed by orally available Casein Kinase 1d inhibitors

**Poster #070 (Saturday March 21<sup>st</sup>) – TMTcalibrator<sup>+</sup> reveals biomarkers of microglial activation in AD CSF**

Novel strategy for identifying low-abundant disease-relevant biomarkers delivers early signals of neuroinflammation in Alzheimer's disease cerebrospinal fluid

Dr. Ian Pike, Chief Operating Officer of Proteome Sciences, who will be attending the conference, commented:

“We are delighted that four different aspects of our proteomics research in Alzheimer's disease have been selected for presentation in Nice. The AD/PD conference is an important venue for dissemination of the latest biomarker and drug development research and presents us with a great opportunity to showcase our expertise to potential partners and clients.

“We have made very significant contributions to improving the way we can discover and validate disease-relevant biomarkers that have the potential to rapidly translate from discovery into diagnostic assay development. Our CK1d inhibitor program has also progressed strongly and the use of SysQuant<sup>®</sup> has allowed us to demonstrate that many of the pathways affected by worsening tau pathology in human disease are reversed in a rodent model treated with PS110 and PS278-05, our two lead inhibitors.”

More details will be available at [www.proteomics.com](http://www.proteomics.com)

**ENDS**

**For further information please contact:**

**Proteome Sciences plc**

Christopher Pearce, Executive Chairman  
Dr. Ian Pike, Chief Operating Officer  
Geoff Ellis, Finance Director

Tel: +44 (0)1932 865065

**Nominated Adviser**

**Cenkos**

Mark Connelly/Callum Davidson

Tel: +44 (0)20 7397 8900

**finnCap**

Geoff Nash

Tel : +44 (0)20 7220 0563

**Public Relations**

**IKON Associates**

Adrian Shaw

Email: [adrian@ikonassociates.com](mailto:adrian@ikonassociates.com)

Tel: +44 (0)1483 271291

Mobile +44(0)7979 900733

**Notes for editors:**

**About Proteome Sciences plc ([www.proteomics.com](http://www.proteomics.com))**

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

The Company's PS Biomarker Services<sup>™</sup> division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.